Every evidence profile is built from primary human trial data, labelled by evidence tier, and honest about what the research doesn't yet support. Medically reviewed before publication. No supplement sales. No advertorial.
Read The Compound — our editorial research blogEvidence framework
Every compound profile is assigned an evidence tier based on the quality and depth of the human clinical research available at time of publication.
Direct human experimental evidence. RCTs with control groups, or systematic reviews pooling multiple RCTs. The highest evidentiary standard. Compounds here have demonstrated effects in controlled human studies, not just mechanisms or animal data.
Strong mechanistic rationale confirmed in human biology, supported by observational or cohort studies. Clinical outcomes in humans are not yet established by RCT. Warrants attention — but not the same confidence as Tier 1.
Early-stage human evidence: case reports, pilot studies, or small open-label trials without controls. Mechanistically plausible but insufficiently studied in humans to draw clinical conclusions. Presented for completeness, not recommendation.
Featured research
Five compound profiles drawn from our editorial research blog — each traceable to primary sources.
The first powered human RCT of rapamycin for longevity. What the PEARL data actually shows — and where the limits of the evidence sit.
Semaglutide and liraglutide — the clinical evidence base, the compounding question, and what the regulatory landscape means for UK patients.
NMDA antagonism, FDA-approved esketamine, and the evidence for ketamine-assisted therapy in treatment-resistant depression and beyond.
NHANES epidemiology, the Traverse Trial cardiovascular safety data, and what it means for men considering testosterone replacement in the UK.
The addiction-interruption evidence, the cardiac QT-prolongation risk, and what the Stanford trial data means for patients seeking ibogaine abroad.
Editorial standards
Every piece on ProvenLongevity is held to four principles. These are not aspirational — they are gates that every piece of content must pass before publication.
We cite the original trial, not a press release about it. Every factual claim carries a reference to the primary source — journal, authors, year.
No therapeutic claims that imply diagnosis or treatment of disease. We describe what the evidence shows, not what a compound does to your health.
Compounds are ranked by evidence quality, not by who paid us. We do not sell sponsored placement in evidence profiles or research hub listings.
Every claim carries its evidence tier — Tier 1, 2, or 3. Claims without a tier assignment do not appear on the platform.